Background. Nebivolol is a highly selective β1-adrenoreceptor antagonist with vasodilating
properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) …

Nebivolol has been adequately tested in clinical efficacy trials of patients with mild
hypertension. Clinical efficacy trials or their metaanalyses did not accurately predict the …

Background Most patients with hypertension require more than one antihypertensive to
achieve blood pressure (BP) control. Objective The purpose of this trial was to assess the …

Nebivolol is a β-blocker under US Food and Drug Administration review for the treatment of
hypertension. The unique pharmacologic properties of nebivolol include high specificity for …

Nebivolol, compared with classical β-blockers, exerts a high selectivity for β-adrenergic
receptors and also reduces peripheral vascular resistance by modulating nitric oxide (NO) …

Background: In patients with diabetes mellitus type 2 and arterial hypertension, the control of
systolic and diastolic blood pressure is essential to reduce the risk of adverse events. The …

Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the
highly beta 1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the …

Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-
blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database …

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, safety,
economic issues, dosage, and place in therapy of nebivolol are reviewed. Summary …

Nebivolol is a highly selective β 1-adrenergic receptor antagonist with a pharmacologic
profile that differs from those of other drugs in its class. In addition to cardioselectivity …